antileukemic

antileukemic

1. KSC (40mg/kg) enhanced markedly the antileukemic and immunopotentiating activities of T AK/L IL 2 therapy. The rate of life prolongation was 36%,and the cure rate of the leukemia mice was doubled.

KSC（40mg/kg）对T－AK/L－IL－2的抗白血病作用有明显的增强效应，荷瘤小鼠细胞免疫功能进一步增强，生命延长率、长期存活率分别提高36%和99.9%。

2. Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy.

MRD作为抗白血病药物疗效标志,被用于评估患者危险,在某些病例中也用于调整治疗强度。

3. Study of antileukemic effect of CpG-oligodeoxynucleotides treated cord blood

含CpG基序的寡核苷酸介导的脐血抗白血病细胞作用的研究

4. METHODS :Leukemic cells from patients with acute leukemia were treated with different antileukemic agents in microwell liquid culture,then the cytotoxicity was measured with MTT assay.

方法： 将白血病细胞与化疗药物微孔液体培养，MTT法检测细胞毒性。

5. METHODS:Leukemic cells from patients with acute leukemia were treated with different antileukemic agents in microwell liquid culture,then the cytotoxicity was measured with MTT assay.

方法：将白血病细胞与化疗药物微孔液体培养，MTT法检测细胞毒性。

6. Keywords killer cells;natural;antileukemic activity;disease model;animal;mice;

杀伤细胞;天然;抗白血病活性;疾病模型;动物;小鼠;

7. Antileukemic activity induced by DCs cross presenting apoptotic APL cells lysate antigen

树突状细胞对APL凋亡细胞溶解抗原交叉提呈诱导产生的抗白血病效应

8. Objective:To evaluate the antileukemic activity and side effects of topotecan-based induction therapy in patients with refractory and relapsed acute myelogenous leukemia(AML).

目的 :评价以拓扑替康为基础的联合诱导方案治疗难治及复发急性粒细胞白血病 (AML)的疗效及不良反应。